SCHEMBL5253633

SCHEMBL5253633

CC(C)(C)OC(=O)CNCc1c(C(=O)O)ncn1CCSc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ VSIR Q9H7M9 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MTNR1A P48039 1/20 0.32
▸ MTNR1B P49286 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CCNE2 O96020 1/20 0.32
▸ CCNE1 P24864 1/20 0.32
▸ CDK2 P24941 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5185419 0.90 LMNA (0.37) SMN1; SMN2L3MBTL1GAAMAPTTDP1
SCHEMBL5256146 0.80 SMN1; SMN2 (0.33) SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5257291 0.80 SMN1; SMN2 (0.38) SMN1; SMN2VSIRL3MBTL1MTNR1AMTNR1B
SCHEMBL5264729 0.77 L3MBTL1 (0.34) VSIRL3MBTL1GAAF2MAPT
SCHEMBL5257194 0.76 PKM (0.43) SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5256250 0.75 PKM (0.45) SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5185657 0.74 ALDH1A1 (0.35) SMN1; SMN2VSIRL3MBTL1CYP1A2CYP2D6
SCHEMBL5255298 0.71 PKM (0.58) SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5185606 0.68 GAA (0.43) SMN1; SMN2L3MBTL1CYP1A2CYP2D6CYP2C9
SCHEMBL5187026 0.68 NPC1 (0.44) SMN1; SMN2L3MBTL1GAAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1798231-A2 Intermediate products for the preparation of antibacterial compounds NOVEXEL (FR) 2007-06-20 — — EP disclosed
EP-1399444-B1 NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS NOVEXEL (FR) 2007-04-11 — — EP disclosed
EP-1399444-A2 NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS Aventis Pharma S.A. (FR) 2004-03-24 — — EP disclosed
WO-2002100860-A2 HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS AVENTIS PHARMA S.A. (FR) 2002-12-19 — — WO disclosed
Send feedback